MASS — 908 Devices Inc.

Summary of 908 Devices Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $13.4 million, a 14% increase year-over-year from $11.8 million.
• Handheld Product and Service Revenue: $12.8 million, up 16% from $11 million, driven by FTIR products.
• Gross Profit: $6.9 million, with a gross margin of 51%, improved from 47% in the prior year.
• Adjusted Gross Profit: $7.7 million, with an adjusted gross margin of 57%.
• Net Loss: $12 million, compared to a net loss of $9.8 million in Q1 2025, primarily due to a $3.9 million noncash charge.
• Adjusted EBITDA: Loss of $2.5 million, an improvement from a loss of $4.6 million in the prior year.
• Cash Position: Ended the quarter with $111.7 million in cash, cash equivalents, and marketable securities, with no debt.

2. Strategic Updates and Business Highlights

• Customer Base: Sales to U.S. state and local customers accounted for approximately 50% of revenue, with consistent order growth.
• Acquisition of NIRLAB AG: A strategic move to enhance drug detection capabilities and expand recurring revenue through a high-retention subscription model. The acquisition is expected to add approximately $2.5 million in revenue for 2026.
• Product Launches: Continued momentum with the VipIR product, which is expected to significantly contribute to revenue growth in 2026.
• Operational Efficiency: The company has streamlined its cost structure and improved its balance sheet, positioning itself for sustained growth.

3. Forward Guidance and Outlook

• Revenue Guidance for 2026: Expected to be in the range of $67 million to $70 million, representing a growth of 19% to 25% year-over-year.
• Handheld Product and Service Revenue Growth: Anticipated to grow 18% to 21% year-over-year, contributing $62 million to $64 million.
• Adjusted EBITDA Loss: Expected to reduce to mid-single-digit millions, with NIRLAB contributing approximately $1 million to the adjusted EBITDA loss in 2026 but projected to be profitable in 2027.

4. Bad News, Challenges, or Points of Concern

• Increased Net Loss: The net loss widened due to noncash charges, which could raise concerns about financial health despite revenue growth.
• Recurring Revenue Decline: Recurring revenue decreased by 7% year-over-year, primarily due to a reduction in Mass Spec service revenue.
• Integration Risks: While the acquisition of NIRLAB is seen as strategic, there are inherent risks in integrating new teams and technologies, especially given NIRLAB's current subscale operations in the U.S.

5. Notable Q&A Insights

• NIRLAB Integration: The domestic sales force is expected to quickly start cross-selling NIRLAB products, leveraging existing customer relationships.
• Recurring Revenue Potential: Approximately 40% to 50% of the anticipated $2.5 million from NIRLAB is expected to be recurring, with significant growth anticipated in 2027.
• Funding Visibility: There is optimism regarding the flow-through of federal funding to state and local customers, which may support growth momentum throughout 2026.
• Pricing Power: The company believes it has strong pricing power due to the differentiated nature of its products, which could enhance recurring revenue opportunities.

Overall, 908 Devices reported solid revenue growth and strategic advancements, particularly with the acquisition of NIRLAB, while also facing challenges related to net losses and declining recurring revenue. The outlook for 2026 remains positive, with expectations for continued growth and operational improvements.